Results from the mADCS-CGIC showed 40 % of citalopram participants having moderate or marked improvement from baseline compared with 26 % of placebo recipients , with estimated treatment effect ( odds ratio [ OR ] of being at or better than a given CGIC category ) of 2.13 ( 95 % CI , 1.23-3 .69 ) , P = .01 .